Asunaprevir for hepatitis C: a safety evaluation

Expert Opinion on Drug Safety
I GentileG Borgia

Abstract

The introduction of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV) chronic infection. Non-structural 3 protease inhibitors are currently the most numerous class of DAAs on the market. This review mainly focuses on the tolerability and safety profile of asunaprevir (ASV)-containing DAA regimens. ASV is a second-wave protease inhibitor currently in Phase III clinical development in most countries and already available in Japan. ASV shows potent antiviral effect and clinical efficacy on HCV genotypes 1 and 4. The all-oral combination daclatasvir/ASV reached high eradication rates in HCV genotype 1b and 4 infection, and a lower efficacy in genotype 1a infection. ASV presents a low potential for drug-drug interaction and a good tolerability as part of multiple, including all-oral, regimens. ASV is associated with a transient and usually mild increase in aminotransferase levels in a low percentage of cases. Due to the impaired pharmacokinetic profile observed in advanced liver disease, ASV use in patients with moderate or severe hepatic impairment is not allowed. In conclusion, ASV represents a powerful weapon against HCV infection and has to be considered an optimal option as a compo...Continue Reading

References

Aug 17, 2001·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·G BorgiaM Piazza
Mar 18, 2003·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Guglielmo BorgiaMarcello Piazza
May 6, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Ivan GentileGuglielmo Borgia
Aug 27, 2005·The Lancet Infectious Diseases·Colin W ShepardMiriam J Alter
Jan 7, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vincent SorianoStefan Zeuzem
Feb 4, 2009·Best Practice & Research. Clinical Gastroenterology·Bernd Kronenberger, Stefan Zeuzem
Mar 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN American Association for the Study of Liver Diseases
May 1, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE1 Study Team
Nov 12, 2009·The Journal of Antimicrobial Chemotherapy·Tara L KiefferGaston R Picchio
Dec 17, 2009·Expert Opinion on Investigational Drugs·Ivan GentileGuglielmo Borgia
Mar 30, 2010·Journal of Hepatology·Ivan Gentile, Guglielmo Borgia
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Sep 8, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN American Association for Study of Liver Diseases
Oct 12, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kazuaki ChayamaHiromitsu Kumada
Jan 20, 2012·The New England Journal of Medicine·Anna S LokClaudio Pasquinelli
Feb 4, 2012·Journal of Hepatology·Christoph SarrazinJean-Michel Pawlotsky
Apr 18, 2012·Antimicrobial Agents and Chemotherapy·Fiona McPheeClaudio Pasquinelli
Nov 10, 2012·Journal of Gastroenterology and Hepatology·Catherine A M Stedman
Jan 4, 2013·The New England Journal of Medicine·Edward J GaneM Michelle Berrey
Feb 27, 2013·Drug Design, Development and Therapy·Philippe A Gallay, Kai Lin
May 21, 2013·World Journal of Gastroenterology : WJG·Filomena MoriscoNicola Caporaso
Nov 13, 2013·Expert Opinion on Pharmacotherapy·Ferdinando FuscoIvan Gentile
Jan 1, 2014·Current Medicinal Chemistry·I GentileG Borgia
Mar 7, 2014·Expert Opinion on Investigational Drugs·Ivan GentileGuglielmo Borgia
Mar 8, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hiromitsu KumadaEric Hughes
Mar 29, 2014·Expert Opinion on Investigational Drugs·Ivan GentileGuglielmo Borgia
May 21, 2014·Expert Review of Anti-infective Therapy·Ivan GentileGuglielmo Borgia
May 23, 2014·Expert Opinion on Investigational Drugs·Ivan GentileGuglielmo Borgia
Jun 3, 2014·Reviews on Recent Clinical Trials·Ivan GentileGuglielmo Borgia
Jun 12, 2014·Expert Review of Anti-infective Therapy·Ivan GentileGuglielmo Borgia
Jul 6, 2014·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Floriano RosinaUNKNOWN Italian Society of Gastroenterology SIGE
Jul 10, 2014·Current Medicinal Chemistry·Ivan GentileGuglielmo Borgia
Jul 26, 2014·Therapeutics and Clinical Risk Management·Ivan GentileGuglielmo Borgia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.